Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for relapsed disease

The protease inhibitors (PI) actively using for the treatment of chronic hepatitis C (CHC).The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and relapses.Material and methods. Analysis of the cost...

Full description

Bibliographic Details
Main Authors: A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
Format: Article
Published: Journal Infectology 2016-04-01
Series:Žurnal Infektologii
Online Access:https://journal.niidi.ru/jofin/article/view/466